InsidersTradesSigma
Follow the Lixte Biotechnology Holdings, INC. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, Lixte Biotechnology Holdings, INC. has logged 21 public disclosures. Market capitalisation: €125.4m. The latest transaction was reported on 17 April 2026 (Attribution). Among the most active insiders: FORMAN ERIC. Every trade is free.
21
Insider Decl.
n/a
Thresholds
€147,061
13 ops.
Buy Volume
n/a
n/a
Sell Volume
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 April 2026
Declarations21 total
25,000 sharesCommon StockSEC:0001493152-26-017856:0
25,000 sharesCommon StockSEC:0001493152-26-017852:0
25,000 sharesCommon StockSEC:0001493152-26-017853:0
25,000 sharesCommon StockSEC:0001493152-26-017854:0
350,000 sharesCommon StockSEC:0001493152-26-017855:0
50,000 sharesCommon StockSEC:0001493152-26-017857:0
4,473 shares@ US$2.2916.4% of flowCommon StockSEC:0001493152-23-036424:0
Canonical exit: 31 Dec 2023 (T+90)
10,000 shares@ US$2.8034.6% of flowCommon StockSEC:0001493152-23-036422:0
Canonical exit: 1 Jan 2024 (T+90)
4,473 shares@ US$2.2916.4% of flowCommon StockSEC:0001493152-23-035712:0
Canonical exit: 31 Dec 2023 (T+90)
10,000 shares@ US$0.495.9% of flowCommon StockSEC:0001493152-23-000449:0
Canonical exit: 30 Mar 2023 (T+90)
10,000 shares@ US$4.9059.5% of flowCommon StockSEC:0001493152-23-000255:0
Canonical exit: 30 Mar 2023 (T+90)
15,000 shares@ US$0.5112.1% of flowCommon StockSEC:0001493152-22-035794:0
Canonical exit: 15 Mar 2023 (T+90)
10,000 shares@ US$0.6063.2% of flowCommon StockSEC:0001493152-22-035281:0
Canonical exit: 9 Mar 2023 (T+90)
10,000 shares@ US$0.619.8% of flowCommon StockSEC:0001493152-22-035280:0
Canonical exit: 12 Mar 2023 (T+90)
1,457 shares@ US$0.568.8% of flowCommon StockSEC:0001493152-22-033573:0
Canonical exit: 19 Feb 2023 (T+90)
2,400 shares@ US$0.57100.0% of flowCommon StockSEC:0001493152-22-033261:0
Canonical exit: 19 Feb 2023 (T+90)
4,852 shares@ US$0.539828.0% of flowCommon StockSEC:0001493152-22-033084:0
Canonical exit: 15 Feb 2023 (T+90)
52,500 shares@ US$0.5345.3% of flowCommon StockSEC:0001493152-22-032564:0
Canonical exit: 12 Feb 2023 (T+90)
1,333,333 shares0Common StockSEC:0001493152-22-009303:0
34,000 sharesCommon stockSEC:0001493152-16-007181:0
2,500 sharesCommon stockSEC:0001493152-16-007181:1
Canonical exit: 4 May 2016 (T+90)
21 of 21 declarations
About Lixte Biotechnology Holdings, INC.
Lixte Biotechnology Holdings, INC. is a company focused on developing cancer treatments. It specializes in discovering new therapies and technologies in the biotechnology sector.